The duration of the trial for each subject is expected to be 24 months. The duration for each individual patient includes 6 months first-line therapy according to treating physicians choice with HLA ligandome analyses of chronic lymphatic leukaemia cells and selection of patient-individual multi-peptide vaccine being performed in parallel, 12 months study treatment and 6 months follow-up time. The overall duration of the trial is expected to be approximately 4 years including preparatory phase. Recruitment of subjects will start in 06/2016. The end of study is determined as the date of the last visit of the last patient (Last Subject Out (LSO) 01/2020).